Normal View Two Column View Social View MX / DE
Healthcare Market Research

VIDEO: Our Take on ASCO 2018 - Part 1

In this Part 1, Array Biopharma’s RAF/MEK combination, encorafenib and binimetinib, nicknamed COMBO450, posted a median overall survival of 33 months in BRAF-mutated melanoma in the COLUMBUS trial.  This new combination, likely to be approved by the end of June 2018, may be well-positioned to challenge Genentech/Roche’s and Novartis’ respective RAF/MEK combinations which have not surpassed 30 months in OS in trials.